Neuroendocrine Tumors - Pipeline Insight, 2024

This “Neuroendocrine Tumors- Pipeline Insight, 2024” report provides comprehensive insights about 115+ companies and 130+ pipeline drugs in Neuroendocrine Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Neuroendocrine Tumors: Understanding

Neuroendocrine Tumors: Overview

A neuroendocrine cancer, often referred as a neuroendocrine tumor (NET) or neuroendocrine neoplasm, begins in the specialized cells of the body’s neuroendocrine system. These cells have traits of both hormone-producing endocrine cells and nerve cells. They are found throughout the body’s organs and help control many of the body’s functions. Hormones are chemical substances that are carried through the bloodstream to have a specific effect on the activity of other organs or cells in the body. Most NETs take years to develop and grow slowly. However, some NETs can be fast-growing.

Various types of neuroendocrine tumors (NET) may form in many places in the body and grow differently. Many NETs first appear in the lungs or the gastrointestinal tract, including the stomach, pancreas, appendix, intestines, colon and rectum. NETs may also appear in the thymus, thyroid gland, adrenal gland and pituitary gland.
Neuroendocrine tumors (NETs) can be discovered for many different reasons because there is no single set of common symptoms. Symptoms are changes that one can feel in their body. In its early stages, a NET often causes no symptoms and may only be detected during an unrelated x-ray or surgery for another condition. If a person with a NET has symptoms, those symptoms may be associated with the size and/or location of the tumor or with the release of hormones, such as carcinoid syndrome.

Neuroendocrine tumors may be found as an incidental finding or may be suspected from clinical symptoms. When NETs cause clinical symptoms from secreted hormones, they are termed “functioning”. Most NETs do not produce a biologically active hormone and are termed “nonfunctioning.” Both functioning and nonfunctioning NETs tend to present late with nonspecific symptoms that are often attributed to an alternative diagnosis.
The diagnosis of a NET requires a coordinated multidisciplinary effort involving medical oncologists, surgeons, interventional radiologists and pathologists. Results from pathology testing, hormonal testing, and diagnostic and functional imaging are integrated to form a comprehensive diagnostic picture.

There are many tests used for diagnosing a NET. Not all tests described here will be used for every person. Most NETs are found unexpectedly when people have x-rays or a medical procedure done for reasons unrelated to the tumor. If a doctor suspects a NET, they will ask for a complete medical and family history and perform a thorough physical examination. In addition, the following tests may be used to diagnose a NET such as Biopsy, Blood/urine tests, Biomarker testing of the tumor, endoscopy, etc.
The treatment plan may include medications to destroy cancer cells. Medication may be given through the bloodstream to reach cancer cells throughout the body. When a drug is given this way, it is called systemic therapy. Most localized NETs are successfully treated with surgery alone. The surgeon will usually remove some tissue surrounding the tumor, called a margin, in an effort to leave no traces of cancer in the body. If removing a NET using surgery is not possible, it is called an “inoperable” tumor. In these situations, the doctor will recommend another treatment plan. Medication may also be given locally, which is when the medication is applied directly to the cancer or kept in a single part of the body. This treatment is generally prescribed by a medical oncologist, a doctor who specializes in treating cancer with medication.

"Neuroendocrine Tumors- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neuroendocrine Tumors pipeline landscape is provided which includes the disease overview and Neuroendocrine Tumors treatment guidelines. The assessment part of the report embraces, in depth Neuroendocrine Tumors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neuroendocrine Tumors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Neuroendocrine Tumors R&D. The therapies under development are focused on novel approaches to treat/improve Neuroendocrine Tumors.

Neuroendocrine Tumors Emerging Drugs Chapters

This segment of the Neuroendocrine Tumors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Neuroendocrine Tumors Emerging Drugs

RYZ101: RayzeBio, Inc.

RYZ101 is an investigational, targeted RPT designed to deliver a highly potent alpha-emitting radioisotope, Actinium-225 (Ac225), to solid tumors expressing SSTR2. RYZ101 leverages DOTATATE, a known binder and linker used in other radiopharmaceutical produts. RYZ101 uses Ac225 instead of the Lu177 used in Lutathera and thus delivers hundreds of times more potency in cancer cell killing. The higher potency of RYZ101 can provide significant clinical benefit to patients. RYZ101 utilizes a proprietary and patent protected formulation. The drug is being developed for gastroenteropancreatic neuroendocrine tumor, pancreatic net, neuroendocrine tumors, extensive stage small cell lung cancer (ES-SCLC), and other tumors.

SVV-001: Seneca Therapeutics

SVV-001, an oncolytic virus of the genus Seneca in the Picornaviridae family. SVV-001 is characterized by its ability to replicate selectively in certain human tumor cells (“SVV-permissive cells”), namely those that express TEM8, the receptor of SVV. SVV-001 is non-pathogenic in humans and animals. SVV-001 and the Seneca genus was originally discovered in 2001 at Novartis Pharmaceuticals by Dr. Paul Hallenbeck. SVV-001 was further developed as a novel cancer therapeutic at Neotropix, Inc. SVV-001 has been extensively tested in over 30 non-clinical cancer models, including immunotherapeutic settings, and in three clinical trials for various solid cancer namely neuroendocrine tumors such as carcinoids, small cell lung cancer and a variety of pediatric cancers. These trials confirmed the safety of intravenous dosing of SVV-001 and safety along with suggestions of significant clinical benefit. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

Voyager-V1: Vyriad, Inc.

VSV-IFNβ-NIS (Voyager V1; VV1) is derived from VSV, a bullet-shaped, negative-sense RNA virus with low human seroprevalence; it is engineered to replicate selectively in and kill human cancer cells. VV1 encodes hIFNβ to increase antitumoral immune response and tumor specificity, plus the thyroidal sodium iodide symporter NIS to allow imaging of virus. VV1 is synergistic with different anti-PD-(L)1 antibodies in several tumor models. Currently the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

ADCT-701: ADC Therapeutics

ADCT-701 is an ADC composed of a humanized IgG1 antibody against human DLK-1, site-specifically conjugated using Glycoconnect technology to PL1601, which contains a valine-alanine cleavable linker and the PBD dimer cytotoxin SG3199. In vitro, ADCT-701 demonstrated potent cytotoxicity in a panel of human cancer cell lines of different origin and levels of DLK-1, while its potency was strongly reduced in DLK-1-negative cell lines. In vivo, ADCT-701 showed potent anti-tumor activity in the DLK1-expressing neuroblastoma-derived SK-N-FI xenograft in which a single dose of ADCT-701 at 0.5 or 1 mg/kg showed dose-dependent anti-tumor activity compared to the vehicle- and isotype control ADC-treated mice. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

Neuroendocrine Tumors: Therapeutic Assessment

This segment of the report provides insights about the different Neuroendocrine Tumors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Neuroendocrine Tumors

There are approx. 115+ key companies which are developing the therapies for Neuroendocrine Tumors. The companies which have their Neuroendocrine Tumors drug candidates in the most advanced stage, i.e. Phase III include, RayzeBio.

Phases

This report covers around 130+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Neuroendocrine Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Neuroendocrine Tumors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neuroendocrine Tumors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neuroendocrine Tumors drugs.

Neuroendocrine Tumors Report Insights

• Neuroendocrine Tumors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Neuroendocrine Tumors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Neuroendocrine Tumors drugs?
• How many Neuroendocrine Tumors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neuroendocrine Tumors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Neuroendocrine Tumors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Neuroendocrine Tumors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ipsen
• Shenzhen Chipscreen Biosciences Co., Ltd.
• Hutchison Medipharma Limited
• RayzeBio, Inc.
• Amgen
• Camurus
• BeiGene
• EpicentRx
• GlaxoSmithKline
• Crinetics Pharmaceuticals
• Eli Lilly and Company
• Seneca Therapeutics
• ADC Therapeutics
• Vyriad, Inc.

Key Products

• Irinotecan liposome
• Chiauranib
• Surufatinib
• RYZ101
• Tarlatamab
• CAM2029
• Tislelizumab
• RRx-001
• Socazolimab
• Paltusotine
• Ramucirumab
• SVV-001
• ADCT-701
• Voyager-V1

This product will be delivered within 3-5 business days.